Table 4 Associations of cystatin C with incident CKD and all-cause mortality in various subgroups.

From: Associations of cystatin C with incident chronic kidney disease and all-cause mortality in patients with normal glucose tolerance and prediabetes

 

Adjusted hazard ratio (95% CI)a

P

Overall (n = 146)

2.96 (1.09, 8.09)

0.034

Age < 65 years (n = 102)

2.79 (0.64, 12.19)

0.173

Age ≥ 65 years (n = 44)

4.63 (0.87, 24.67)

0.072

Male (n = 121)

2.40 (0.79, 7.28)

0.122

Female (n = 25)

3.96 (0.36, 43.55)

0.261

Body mass index < 25 kg/m2 (n = 61)

2.37 (0.58, 9.60)

0.228

Body mass index ≥ 25 kg/m2 (n = 85)

4.33 (0.94, 19.88)

0.059

Systolic blood pressure < 130 mm Hg (n = 84)

2.77 (0.66, 11.55)

0.162

Systolic blood pressure ≥ 130 mm Hg (n = 62)

4.01 (0.97, 16.59)

0.055

Normal glucose tolerance (n = 72)

1.52 (0.26, 9.04)

0.643

Prediabetes (n = 74)

5.75 (1.34, 24.69)

0.019

No use of ACEI or ARB (n = 75)

3.10 (0.87, 11.03)

0.080

Use of ACEI or ARB (n = 71)

4.20 (0.74, 23.79)

0.105

  1. CKD chronic kidney disease, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker. aAdjusted for age, sex, body mass index, systolic blood pressure, smoking, prediabetes (vs. normal glucose tolerance), use of ACEI or ARB, and urine albumin to creatinine ratio.
Back to article page